Marcel Kloosterman
Director @ Brightlands Venture Partners
Maastricht, The Netherlands
Marcel Kloosterman is a Series A investor at Brightlands Venture Partners in Maastricht focused on Medical and Health Care. Marcel has worked for DSM since 1985 in various functions ranging from market research and business development to new business creation before joining DSM Venturing. His fields of interest and expertise span the areas of Life Sciences, Performance Materials and Clean Tech. Since 2006 he has been part of his time investment manager for LimburgVentures, where he holds several board positions in portfolio companies. Since 2010, Marcel is also part of his time active as investment manager for Nedermaas High Tech Ventures. Marcel is active in various European advisory board councils.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Marcel Kloosterman invests in
Stages Marcel Kloosterman invests in
Countries Marcel Kloosterman invests in
Investment Focus
Industry
- Medical 3 (50%)
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Medical Device 2 (33%)
- Life Science 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Series C 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- The Netherlands 3 (50%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hy2Care
|
Hy2Care BV is a business start-up of the University of Twente, the Netherlands. It is Hy2Care’s ambition to introduce into the market the first cure for Osteoarthritis, the injectable hydrogel.Osteoarthritis is the 4th leading cause of mobility associated disability and affects more than 100 million patients in the Western world, who are all inneed for an effective treatment.It is the aim of Hy2Care to change the future for patients suffering from osteoarthritis. | $5M / Venture - Series Unknown / May 14, 2025 | |
Health Value Creation
|
Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocarclosure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation. | $2.2M / Series A / Dec 22, 2017 | |
Q Chip
|
Q Chip is a biopharmaceutical drug delivery company developing a range of sustained-release biogeneric and biotherapies products (Q-Spheraâ„¢). | $6M / Series C / May 20, 2011 | |
FABPulous
|
FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. | Series A / Jan 11, 2010 | |
|
FABPulous
|
FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. | $1.9M / Series B | |
|
Hy2Care
|
Hy2Care BV is a business start-up of the University of Twente, the Netherlands. It is Hy2Care’s ambition to introduce into the market the first cure for Osteoarthritis, the injectable hydrogel.Osteoarthritis is the 4th leading cause of mobility associated disability and affects more than 100 million patients in the Western world, who are all inneed for an effective treatment.It is the aim of Hy2Care to change the future for patients suffering from osteoarthritis. | $4.1M / Series A |
Co-Investors
About Brightlands Venture Partners
Brightlands Venture Partners is an independent regional venture capital fund manager in the south of the Netherlands. They are an ecosystem investor, investing in companies with a link to one of the Brightlands campuses. The management company has three funds under management: Limburg Ventures, Chemelot Ventures and Brightlands Agrifood Fund. Whilethe funds are for the larger part privately funded, we seek to complement this by financing from public sources to extend our reach.
Brightlands Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Kim de Boer
Partner
|
|||
Casper Bruens
Founder,Managing Partner & Director
|
|||
|
Marcel Kloosterman
Director
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marcel Kloosterman invest in?
Marcel Kloosterman invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Marcel Kloosterman last invest?
The most recent investment recorded for Marcel Kloosterman closed in May 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
